YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and ...

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 milli ...

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the ...

An Instagram post about the last two northern white rhinos references a scenario conservationists have warned us about for ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Triple Doctor, Berenika Maciejewicz, serves as the company’s Chief Scientific Advisor merging AI, computational biology ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and ...

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

The future of clinical development hinges on viewing biological systems holistically. By integrating diverse molecular data ...